20-F: XTL Biopharmaceuticals Reports Financial Results for Fiscal Year 2023, Outlines Strategic Shift Towards AI

XTL Biopharmaceuticals reports a net loss for 2023 and announces a strategic shift by entering into a term sheet to acquire The Social Proxy, an AI web data company.

Summary

• XTL Biopharmaceuticals reported its financial results for the fiscal year ended December 31, 2023.
• The company incurred a net loss of $1.782 million, or $0.003 per share.
• As of December 31, 2023, XTL had approximately $1.401 million in cash and cash equivalents.
• The company is shifting its strategic focus by entering into a binding term sheet to acquire The Social Proxy, an AI web data company, for $430,000 plus 44.6% of XTL's share capital.
• XTL has secured a $1.5 million private placement contingent on the Social Proxy acquisition.
• The company's lead drug candidate, hCDR1, remains a Phase II-ready asset for SLE and Sjogren's Syndrome, but research and development expenditures have been reduced pending funding or a strategic partnership.
• XTL had no employees as of April 30, 2024, relying on four part-time service providers.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is pursuing a strategic shift into AI, it is also reporting losses and reducing R&D spending. The future success of the company is highly dependent on securing funding and successfully integrating the new acquisition.

Positives

• FDA has provided written guidance confirming the acceptability of BILAG as the primary endpoint in planned hCDR1 study.
• Secured a commitment of an investment of an amount of $1,500,000 through a private placement to be consummated upon and subject to the closing of the Transaction.

Negatives

• The company incurred a net loss of $1.782 million for the fiscal year ended December 31, 2023.
• The company has reduced research and development expenditures pending funding or a strategic partnership for hCDR1.
• As of April 30, 2024, the company had no employees, relying on four part-time service providers.

Risks

• The company has incurred substantial operating losses since its inception and expects to continue to incur losses in the future.
• Raising additional capital may cause dilution to existing stockholders.
• The company has not yet commercialized any products or technologies.
• Clinical trials may be delayed or unsuccessful.
• The company relies on third parties for clinical trials and manufacturing.
• The company's offices are located in Israel, and the business may be adversely affected by political, economic, and military instability in the Middle East.
• The company may fail to remain in compliance with the continued listing standards of the Nasdaq Capital Market.
• The company is operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine.

Future Outlook

The company plans to continue developing hCDR1, seek strategic partnerships, and identify additional assets to add to its portfolio, subject to receiving adequate financing.

Industry Context

The biopharmaceutical industry is highly competitive, with many companies developing drugs for similar indications. XTL faces competition from larger companies with greater resources and experience.

Comparison to Industry Standards

• GlaxoSmithKline reported that its 2020 sales of Benlysta were up 17% AER (annual equivalent rate), 19% CER (coupon equivalent rate) to 719 million (approximately USD 982 million), including sales of the sub-cutaneous formulation of 354 (approximately USD 483 million) million up 32% AER, 33% CER.
• Global Data estimates the drug sales for SS in 2014 were approximately $990 million in the US and $1.1 billion across the markets covered in its forecast.
• By the end of the forecast period of 2024, sales are estimated to grow to $1.9 billion in the US and $2.2 billion across the markets covered in its forecast with a Compound Annual Growth Rate of 7.2%.

Related Party Transactions

• The company pays to an accounting firm of which the company's CFO is a Partner (accounting firm), a monthly fees of NIS 15 thousand (approximately $4 thousand) for controller and bookkeeping services.
• The company subleases an office from Canndoc Ltd., which is a subsidiary of InterCure Ltd.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of shares in connection with the acquisition of The Social Proxy and the private placement.
• Employees (or service providers) may be affected by the strategic shift and reduction in R&D spending.
• Patients may benefit from the continued development of hCDR1, if funding is secured.
• The company's creditors may be affected by the company's financial performance and ability to raise capital.

Next Steps

• Negotiate definitive agreements and satisfy closing conditions for the acquisition of The Social Proxy.
• Obtain necessary government or third-party approvals for the acquisition.
• Secure full funding or a strategic partner for hCDR1 clinical trials.
• Initiate an international, prospective advanced clinical study intended to assess the safety and efficacy of hCDR1 when given to patients with SLE.
• Initiate a prospective Phase 2 study intended to assess the safety and efficacy of hCDR1 when given to patients with pSS.
• Continually build the company's pipeline of therapeutic candidates.

Key Dates

Keywords

XTL Biopharmaceuticals, hCDR1, Social Proxy, SLE, Sjogrens Syndrome, AI, Acquisition, Financial Results, Biopharmaceutical, Autoimmune Diseases